Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19
Status:
Not yet recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
The novel coronavirus pneumonia is a kind of new emerging respiratory infectious disease,
characterized by fever, dry cough, and chest tightness, and caused by the infection of the
2019 novel coronavirus (2019-nCoV). In severe cases, there will be rapid respiratory system
failure. The novel coronavirus pneumonia is extremely contagious and the disease progresses
rapidly. It has become a urgent and serious public health event that threatens human life and
health globally. Among them, severe pneumonia caused by novel coronavirus is characterized by
extensive acute inflammation of the lungs and the patient is critically ill. At present,
there is no effective treatment in clinical practice.Most of them should receive supportive
care to help relieve symptoms. For severe cases, treatment should include care to support
vital organ functions. This clinical trial is to inspect the safety and efficiency of Human
Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) therapy for severe pneumonia patients
infected with 2019-nCoV.